4 results
Approved WMOSuspended
The primary objective of the study is to compare the progression-free survival (PFS) of REGN2810 (cemiplimab) plus ipilimumab combination therapy (hereinafter referred to as REGN2810/ipi) and REGN2810 plus 2 cycles only of platinum-based doublet…
Approved WMOCompleted
To determine the within and between variability of pharmacokinetic (PK) profiles in patients treated with DOACs in daily practice
Approved WMOCompleted
To evaluate the efficacy of each combination arm, as measured by confirmed objective response rate (ORR)
Approved WMOCompleted
To measure DOAC levels just before surgery of all DOAC patients in the LUMC with elective surgery for which ceasing of DOAC treatment is required.